<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03385135</url>
  </required_header>
  <id_info>
    <org_study_id>ALLIENCE</org_study_id>
    <nct_id>NCT03385135</nct_id>
  </id_info>
  <brief_title>Allopurinol and Endothelial Function in Diabetic CAD Patients</brief_title>
  <acronym>ALLIENCE</acronym>
  <official_title>Impact of ALLopurInol on Endothelial fuNCtion in diabEtic Patients Affected With Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Tunis El Manar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Tunis El Manar</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized trial assessing the impact of allopurinol on endothelial function in
      optimally treated diabetic patients with coronary artery disease. After initial screening,
      subjects were randomized to receive either optimal medical therapy (OMT) + allopurinol or OMT
      alone for 8 weeks. The dose of allopurinol was 300 mg for 4 weeks and 600 mg for 4 weeks with
      a 4-weekly check on hematology and biochemistry
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 2017</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelium-dependent vasodilation</measure>
    <time_frame>2 months</time_frame>
    <description>Brachial Artery Flow-Mediated dilation (FMD)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endothelium-independent vasodilation</measure>
    <time_frame>2 months</time_frame>
    <description>Changes in brachial artery diameter in response to nitrates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL)</measure>
    <time_frame>2 months</time_frame>
    <description>Seattle Angina Questionnaire: a scale that quantifies patients' physical limitations caused by angina, the frequency of and recent changes in their symptoms, their satisfaction with treatment, and the degree to which they perceive their disease to affect their quality of life. Each scale is transformed to a score of 0 to 100, where higher scores indicate better function (eg, less physical limitation, less angina, and better quality of life).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac events (MACE)</measure>
    <time_frame>2 months</time_frame>
    <description>composite of cardiac death, non fatal myocardial infarction and unplanned coronary revascularization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Allopurinol group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Optimal medical therapy associated with allopurinol. The dose of allopurinol is 300 mg for 4 weeks then 600 mg for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Allopurinol group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Optimal medical therapy alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <description>300 mg for 4 weeks then 600 mg for 4 weeks in the active group</description>
    <arm_group_label>Allopurinol group</arm_group_label>
    <other_name>Optimal Medical Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetes type 2

          -  Known coronary artery disease with previous percutaneous coronary intervention and
             optimal medical therapy for at least one month

        Exclusion Criteria:

          -  Pregnant or breast- feeding women

          -  creatinine clearance &lt;60ml/min

          -  Known history of gout disease or ongoing treatment with allopurinol

          -  Allergy to allopurinol

          -  Inability to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salem Kachboura, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cardiology Department, Abderrahmen Mami Hospital, 2008, Ariana</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sami Kasbaoui, MD</last_name>
    <phone>+21622560059</phone>
    <email>kas.sami77@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marouane Boukhris, MD</last_name>
    <phone>+21622557125</phone>
    <email>mar1bou@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardiology Department, Abderrahmen Mami Hospital</name>
      <address>
        <city>Ariana</city>
        <zip>2008</zip>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sami Kasbaoui, MD</last_name>
      <phone>+21622560059</phone>
      <email>kas.sami77@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Marouane Boukhris, MD</last_name>
      <phone>+21622557125</phone>
      <email>mar1bou@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2017</study_first_submitted>
  <study_first_submitted_qc>December 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2017</study_first_posted>
  <last_update_submitted>December 26, 2017</last_update_submitted>
  <last_update_submitted_qc>December 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Tunis El Manar</investigator_affiliation>
    <investigator_full_name>Kasbaoui sami</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>allopurinol</keyword>
  <keyword>coronary artery disease</keyword>
  <keyword>diabetes</keyword>
  <keyword>endothelial function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

